UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glycobiology of cell death: when glycans and lectins govern cell fate

Cell death and differentiation, 2013-08, Vol.20 (8), p.976-986

2013

Volltextzugriff (PDF)

Review article: delivery and efficacy of topical 5‐aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis

Alimentary pharmacology & therapeutics, 2011-05, Vol.33 (9), p.996-1009

2011

Volltextzugriff (PDF)

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Alimentary pharmacology & therapeutics, 2014-10, Vol.40 (8), p.903-916

2014

Volltextzugriff (PDF)

Randomised clinical trial: delayed‐release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing – ASCEND I and II combined analysis

Alimentary pharmacology & therapeutics, 2011-03, Vol.33 (6), p.672-678

2011

Volltextzugriff (PDF)

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Alimentary pharmacology & therapeutics, 2009-08, Vol.30 (3), p.210-226

2009

Volltextzugriff (PDF)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

Gut, 2008-07, Vol.57 (7), p.893-902

2008

Volltextzugriff (PDF)

Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission

Alimentary pharmacology & therapeutics, 2007-10, Vol.26 (7), p.987-1003

2007

Volltextzugriff (PDF)

Review article: 5‐aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5‐aminosalicylate to the colonic mucosa

Alimentary pharmacology & therapeutics, 2008-09, Vol.28 (6), p.663-673

2008

Volltextzugriff (PDF)

MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials

Alimentary pharmacology & therapeutics, 2007-07, Vol.26 (2), p.205-215

2007

Volltextzugriff (PDF)

Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

Alimentary pharmacology & therapeutics, 2010-10, Vol.32 (8), p.990-999

2010

Volltextzugriff (PDF)

Review article: monitoring of immunomodulators in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2005-02, Vol.21 (4), p.307-319

2005

Volltextzugriff (PDF)

Meta‐analysis: factors predicting post‐operative recurrence with placebo therapy in patients with Crohn’s disease

Alimentary pharmacology & therapeutics, 2008-09, Vol.28 (5), p.545-556

2008

Volltextzugriff (PDF)

Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis

Alimentary pharmacology & therapeutics, 2009-03, Vol.29 (6), p.643-653

2009

Volltextzugriff (PDF)

Review article: bowel preparation for colonoscopy – the importance of adequate hydration

Alimentary pharmacology & therapeutics, 2007-09, Vol.26 (5), p.633-641

2007

Volltextzugriff (PDF)

MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

Alimentary pharmacology & therapeutics, 2008-06, Vol.27 (11), p.1094-1102

2008

Volltextzugriff (PDF)

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies

Alimentary pharmacology & therapeutics, 2011-10, Vol.34 (7), p.747-756

2011

Volltextzugriff (PDF)

The relationship between infliximab treatment and lymphoma in Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1999-12, Vol.117 (6), p.1433-1437

1999

Volltextzugriff (PDF)

Treatment of fistulizing Crohn's disease

Gastroenterology (New York, N.Y. 1943), 2000-10, Vol.119 (4), p.1132-1147

Lichtenstein, Gary R.

2000

Volltextzugriff (PDF)

Risk factors for early postoperative recurrence of Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1998-08, Vol.115 (2), p.259-267

1998

Volltextzugriff (PDF)

Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma

Gastroenterology (New York, N.Y. 1943), 2000-06, Vol.118 (6), p.1018-1024

2000

Volltextzugriff (PDF)

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials

Alimentary pharmacology & therapeutics, 2012-07, Vol.36 (2), p.126-134

2012

Volltextzugriff (PDF)

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2005-12, Vol.353 (23), p.2462-2476

2005

Volltextzugriff (PDF)

Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation

Alimentary pharmacology & therapeutics, 2007-11, Vol.26 (10), p.1361-1370

2007

Volltextzugriff (PDF)

Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology

The American journal of gastroenterology, 2020-07, Vol.115 (7), p.1007-1018

2020

Volltextzugriff (PDF)

CANCER RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gastroenterology clinics of North America, 1999-06, Vol.28 (2), p.459-477

1999

Volltextzugriff (PDF)

1 – 25 von 861

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(789)
Mit Volltextzugriff
(630)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(511)
Humans
(484)
Life Sciences & Biomedicine
(475)
Biological And Medical Sciences
(241)
Female
(227)
Male
(222)
Medical Sciences
(217)
Adult
(186)
Middle Aged
(165)
Gastroenterology & Hepatology
(151)
Aged
(94)
Risk Factors
(77)
Medicin Och Hälsovetenskap
(76)
Treatment Outcome
(64)
Gastroenterology. Liver. Pancreas. Abdomen
(61)
Pharmacology. Drug Treatments
(52)
Adolescent
(49)
Cardiovascular System & Cardiology
(48)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(48)
Immunology
(45)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Glycobiology of cell death: when glycans and lectins govern cell fate

Review article: delivery and efficacy of topical 5‐aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis

Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study

Randomised clinical trial: delayed‐release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing – ASCEND I and II combined analysis

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission

Review article: 5‐aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5‐aminosalicylate to the colonic mucosa

MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials

Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

Review article: monitoring of immunomodulators in inflammatory bowel disease

Meta‐analysis: factors predicting post‐operative recurrence with placebo therapy in patients with Crohn’s disease

Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis

Review article: bowel preparation for colonoscopy – the importance of adequate hydration

MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies

The relationship between infliximab treatment and lymphoma in Crohn's disease

Treatment of fistulizing Crohn's disease

Risk factors for early postoperative recurrence of Crohn's disease

Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation

Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology

CANCER RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Suchergebnisse filtern